Brady Todd R. 4

What Happened

• Todd R. Brady, a non-employee director of Contineum Therapeutics, was granted a derivative award (stock option) covering 19,000 shares on 2026-06-26. The Form 4 reports an acquisition at $0.00, indicating an option grant rather than a cash purchase or share sale. No cash changed hands and no shares were sold.

Key Details

• Transaction date: 2026-06-26. Transaction type/code: A (award/grant — derivative option).
• Amount: options for 19,000 shares; reported acquisition price: $0.00 (reflects grant).
• Vesting: Options vest in full on the earlier of (i) June 26, 2027 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, subject to continuous service (per footnote).
• Shares owned after transaction: not specified in the filing.
• Timeliness: Filing dated 2026-06-26 for the 2026-06-26 transaction — appears timely.

Context

• This is a routine non-employee director compensation grant under Contineum’s 2024 Equity Incentive Plan and Non-Employee Director Compensation Program (automatic annual grant of 19,000-option awards to continuing directors). It is a grant of options (a derivative), not an exercise or sale — no immediate cash proceeds or market activity resulted from this filing.